Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab
Atypical hemolytic uremic syndrome (aHUS) is a rare, genetic, progressive, life-threatening
form of thrombotic microangiopathy (TMA) predominantly caused by dysregulation of the …
form of thrombotic microangiopathy (TMA) predominantly caused by dysregulation of the …
Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand
LC Fox, SJ Cohney, JY Kausman, J Shortt… - Internal medicine …, 2018 - Wiley Online Library
Thrombotic microangiopathy (TMA) arises in a variety of clinical circumstances with the
potential to cause significant dysfunction of the kidneys, brain, gastrointestinal tract and …
potential to cause significant dysfunction of the kidneys, brain, gastrointestinal tract and …
CARE guidelines for case reports: explanation and elaboration document
Background Well-written and transparent case reports (1) reveal early signals of potential
benefits, harms, and information on the use of resources;(2) provide information for clinical …
benefits, harms, and information on the use of resources;(2) provide information for clinical …
Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification
H Martín Merinero, Y Zhang, E Arjona… - Blood, The Journal …, 2021 - ashpublications.org
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathy
that can progress, when untreated, to end-stage renal disease. Most frequently, aHUS is …
that can progress, when untreated, to end-stage renal disease. Most frequently, aHUS is …
CARE guidelines for case reports: explanation and elaboration document. Translation into Russian
MS Barber, JK Aronson… - Digital …, 2022 - jdigitaldiagnostics.com
BACKGROUND: Well-written and transparent case reports (1) reveal early signals of
potential benefits, harms, and information on the use of resources;(2) provide information for …
potential benefits, harms, and information on the use of resources;(2) provide information for …
[PDF][PDF] Рекомендации CARE для описаний случаев: разъяснения и уточнения
АННОТАЦИЯ Обоснование. Доступное и понятное описание клинических случаев
помогает выявлять самые ранние данные о возможной пользе, неблагоприятном …
помогает выявлять самые ранние данные о возможной пользе, неблагоприятном …
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
LMP Palma, CB Langman - Journal of blood medicine, 2016 - Taylor & Francis
The biology of atypical hemolytic uremic syndrome has been shown to involve inability to
limit activation of the alternative complement pathway, with subsequent damage to systemic …
limit activation of the alternative complement pathway, with subsequent damage to systemic …
Timing of eculizumab therapy for C3 glomerulonephritis
L Rodriguez-Osorio, A Ortiz - Clinical kidney journal, 2015 - academic.oup.com
Eculizumab is an anti-C5 antibody that inhibits C5 cleavage and prevents the generation of
the terminal complement complex C5b-9. Eculizumab is licensed to treat paroxysmal …
the terminal complement complex C5b-9. Eculizumab is licensed to treat paroxysmal …
[HTML][HTML] Challenges in classification of novel CFH variants in patients with atypical hemolytic uremic syndrome
M Sridharan, ML Kluge, RS Go, RS Abraham… - Thrombosis …, 2020 - Elsevier
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA)
characterized by dysregulation of the alternative pathway of complement. Heterozygous …
characterized by dysregulation of the alternative pathway of complement. Heterozygous …
Рекомендации CARE для описания случаев: разъяснения и уточнения
Аннотация Обоснование. Доступное и понятное описание клинических случаев
помогает выявлять самые ранние данные о возможной пользе, неблагоприятном …
помогает выявлять самые ранние данные о возможной пользе, неблагоприятном …